Results

Total Results: 489 records

Showing results for "psa".
Users also searched for: aspirin

41. Prostate-Cancer-Test Research-Protocol (pdf file)
    effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/prostate-cancer-test_research-protocol.pdf
    October 14, 2011 - values, decreased percent-free PSA levels, elevated PSA velocities, complexed PSA, or externally validated … values, decreased percent- free PSA levels, elevated PSA velocities, complexed PSA, or externally validated …  PCA3 comparators ○ Total PSA ○ Percent free PSA ○ PSA velocity ○ Complexed PSA ○ Externally … , percent free PSA, PSA velocity, complexed PSA, externally validated nomograms) KQ3: No PCA3 testing … , % free PSA, PSA velocity, complexed PSA, or externally validated nomograms) in predicting initial

42. Therapies for Clinically Localized Prostate Cancer: Evidence Summary (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/prostate-cancer-therapies-summary.pdf
    September 01, 2020 - clinically localized prostate cancer (CLPC) detected clinically rather than by prostate-specific antigen (PSA … to no mortality difference versus RP or external beam radiation (EBR)+androgen deprivation (AD) in PSA … ProtecT PSA-based active monitoring group is labeled active surveillance in figure. … Absolute effects are likely smaller among PSA-detected CLPC due to its more indolent course. … AM was compared with RP or EBR plus AD in PSA screen–detected CLPC.

43. Therapies for Clinically Localized Prostate Cancer: Evidence Summary (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/prostate-cancer-therapies-summary.pdf
    September 01, 2020 - clinically localized prostate cancer (CLPC) detected clinically rather than by prostate-specific antigen (PSA … to no mortality difference versus RP or external beam radiation (EBR)+androgen deprivation (AD) in PSA … ProtecT PSA-based active monitoring group is labeled active surveillance in figure. … Absolute effects are likely smaller among PSA-detected CLPC due to its more indolent course. … AM was compared with RP or EBR plus AD in PSA screen–detected CLPC.

44. Therapies for Clinically Localized Prostate Cancer: Evidence Summary (pdf file)
    effectivehealthcare-admin.ahrq.gov/sites/default/files/prostate-cancer-therapies-summary.pdf
    September 01, 2020 - clinically localized prostate cancer (CLPC) detected clinically rather than by prostate-specific antigen (PSA … to no mortality difference versus RP or external beam radiation (EBR)+androgen deprivation (AD) in PSA … ProtecT PSA-based active monitoring group is labeled active surveillance in figure. … Absolute effects are likely smaller among PSA-detected CLPC due to its more indolent course. … AM was compared with RP or EBR plus AD in PSA screen–detected CLPC.

45. Layout 1 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/prostate-cancer_executive.pdf
    February 01, 2008 - We focused on baseline PSA levels and Gleason histologic score. … Prostate cancers not detected by PSA testing. … with PSA levels and rate of PSA rise … levels in men with PSA-detected disease. … PSA testing.

46. Layout 1 (pdf file)
    effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/prostate-cancer_executive.pdf
    February 01, 2008 - We focused on baseline PSA levels and Gleason histologic score. … Prostate cancers not detected by PSA testing. … with PSA levels and rate of PSA rise … levels in men with PSA-detected disease. … PSA testing.

47. Overdiagnosis in Prostate Cancer Screening Decision Models: A Contextual Review for the USPSTF (pdf file)
    www.uspreventiveservicestaskforce.org/home/getfilebytoken/KT7vaWK_JSDNNvEmUAjN8d
    May 01, 2018 - Modeling studies suggest that raising the PSA threshold, lengthening the interval of screening, and … PSA screening is superimposed to estimate lead time. … at diagnosis) Generates PSA level per individual at each screen, PSA >4 μg/L at screen referred … (1) increases w ith age w ithin category of Gleason score and PSA. … <1 µg/L) ‡PSA >2.5 µg/L or PSA velocity >0.35 µg/L per year Abbreviations: PSAPC = Prostate-Specific

48. Archived: Prostate Cancer: Screening, 1996 | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/recommendation/prostate-cancer-screening-1996
    January 01, 1996 - , 17 and its role in screening has largely been replaced by PSA. … PSA elevations are not specific for prostate cancer. … suggested that PSA density (the PSA concentration divided by the gland volume as measured by TRUS) may … Other studies suggest that the rate of change (PSA velocity), rather than the actual PSA level, is a … PSA screening for asymptomatic prostate cancer: truth in advertising.

49. 04-E029-1 Summary (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/prostate-cancer-surveillance_executive.pdf
    December 01, 2011 - Two cohorts used PSA density (PSA per volume of prostate tissue) thresholds. … All seven cohorts in the PSA screening era included regular PSA testing. … screening era reported that PSA testing became part of followup protocol after PSA became available. … All six cohorts in the PSA screening era included regular PSA testing as part of followup protocol. … at diagnosis, decreased free-to-total PSA ratio, or more rapid PSA increase, but not comorbidities or

50. 04-E029-1 Summary (pdf file)
    effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/prostate-cancer-surveillance_executive.pdf
    December 01, 2011 - Two cohorts used PSA density (PSA per volume of prostate tissue) thresholds. … All seven cohorts in the PSA screening era included regular PSA testing. … screening era reported that PSA testing became part of followup protocol after PSA became available. … All six cohorts in the PSA screening era included regular PSA testing as part of followup protocol. … at diagnosis, decreased free-to-total PSA ratio, or more rapid PSA increase, but not comorbidities or

51. Archived: Evidence Summary: Prostate Cancer: Screening | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/document/final-evidence-summary43/prostate-cancer-screening-2012
    October 07, 2011 - group (50% received ≥1 PSA test). … Annual PSA for 6 y Annual DRE for 4 y PSA cut point >4.0 µg/L Positive … PSA previously >3.0 µg/L, a PSA increase of 20% over previous year's value or over predicted PSA … < 10 µg/L: 22% PSA 11–29 µg/L: 28% PSA > 30 µg/L: 23% PSA unknown: 27% Age, period of diagnosis, method … < 10 µg/L: 57%  PSA 10–20 µg/L: 26%  PSA > 20 µg/L: 11% PSA unknown: 13% Age at diagnosis, race/ethnicity

52. Screening for Prostate Cancer: Clinical Summary (pdf file)
    www.uspreventiveservicestaskforce.org/home/getfilebytoken/HUjbcP7uLa2SrGpVW4Fbhd
    August 07, 2008 - Insufficient Evidence) Men Age 75 Years or Older Do not screen Grade: D The prostate-specific antigen (PSA … The conventional PSA test cut-point of 4.0 g/L misses some early cancer. … Variations of PSA screening have not yet been demonstrated to improve health outcomes. … If PSA screening reduces mortality, screening every 4 years may be as beneficial as annual screening. … Interventions Clinicians should discuss the potential benefits and known harms of PSA screening with

53. Overdiagnosis in Prostate Cancer Screening Decision Models: A Contextual Review for the USPSTF (pdf file)
    www.uspreventiveservicestaskforce.org/Home/GetFile/1/16812/prostate-models-overdiagnosis/pdf
    May 01, 2018 - Modeling studies suggest that raising the PSA threshold, lengthening the interval of screening, and … PSA screening is superimposed to estimate lead time. … at diagnosis) Generates PSA level per individual at each screen, PSA >4 μg/L at screen referred … (1) increases w ith age w ithin category of Gleason score and PSA. … <1 µg/L) ‡PSA >2.5 µg/L or PSA velocity >0.35 µg/L per year Abbreviations: PSAPC = Prostate-Specific

54. Localized Prostate Cancer | Effective Health Care
    effectivehealthcare.ahrq.gov/decision-aids/prostate-cancer/05.html
    June 08, 2018 - For those men that choose screening, two tests that may be used to detect prostate cancer are: PSA … blood test: A blood test that detects a protein, called prostate-specific antigen (PSA), made by the … This test shows how much PSA is in your blood. … If your PSA levels are higher than normal or have increased over time, your doctor might test you for

55. Measures of Inefficiency | Agency for Healthcare Research and Quality
    www.ahrq.gov/research/findings/nhqrdr/chartbooks/careaffordability/measures3.html
    June 01, 2018 - Services Task Force recommended against screening men age 75 and over with prostate-specific antigen (PSA … Overall Rate: In 2014, 21.1% of men age 40 and over reported a PSA test in the past year (data not shown … Groups With Disparities: In 2014, men ages 40-54 were less likely to receive a PSA test in the past … Among men ages 40-54, Asians were less likely than Whites to receive PSA testing and Blacks were more … Among men age 75 and over, AI/ANs were less likely than Whites to receive PSA testing.

56. Disposition of Comments for PCA3 Testing for the Diagnosis and Management of Prostate Cancer (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/prostate-cancer-test_disposition-comments.pdf
    April 01, 2013 - Current AUA guidelines for PSA screening recommend another serum PSA when presented with an abnormal … values (PSA velocity) if available, free PSA if available, family history, race, etc. are considered … It is likely that tPSA and PSA density are correlated because tPSA is used in the calculation of PSA … serum PSA, this approach introduces the following issues: 1) PSA is used differently for repeat … PSA data.

57. Disposition of Comments for PCA3 Testing for the Diagnosis and Management of Prostate Cancer (pdf file)
    effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/prostate-cancer-test_disposition-comments.pdf
    April 01, 2013 - Current AUA guidelines for PSA screening recommend another serum PSA when presented with an abnormal … values (PSA velocity) if available, free PSA if available, family history, race, etc. are considered … It is likely that tPSA and PSA density are correlated because tPSA is used in the calculation of PSA … serum PSA, this approach introduces the following issues: 1) PSA is used differently for repeat … PSA data.

58. Evidence Summary: Prostate Cancer: Screening | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary/prostate-cancer-screening
    May 08, 2018 - Objective: To systematically review evidence on prostate-specific antigen (PSA)–based prostate cancer … Effectiveness of PSA-Based Screening Key Question 1. … What are the harms of PSA-based screening for prostate cancer and diagnostic follow-up? … Contamination in PLCO control group, and low adherence with single PSA screening in CAP. … ERSPC sites with variable PSA thresholds for positive test results.

59. Psoriatic Arthritis Surveillance Assesment_CER 54_Low (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/arthritis-psoriatric_surveillance.pdf
    March 01, 2013 - Thus, 14 articles were reviewed for PsA. … A new meta-analysis9 found PsA Response Criteria (PsARC) response at 12-14 weeks was significantly … This drug is not approved for PsA. … This drug is not approved for PsA. EPC Investigator felt the conclusions were up to date. … This drug is not approved for PsA. EPC Investigator felt the conclusions were up to date.

60. Psoriatic Arthritis Surveillance Assesment_CER 54_Low (pdf file)
    effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/arthritis-psoriatric_surveillance.pdf
    March 01, 2013 - Thus, 14 articles were reviewed for PsA. … A new meta-analysis9 found PsA Response Criteria (PsARC) response at 12-14 weeks was significantly … This drug is not approved for PsA. … This drug is not approved for PsA. EPC Investigator felt the conclusions were up to date. … This drug is not approved for PsA. EPC Investigator felt the conclusions were up to date.